Open AccessLurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia
Author(s) -
Herbert Y. Meltzer,
Daniel Barrett Share,
Karu Jayathilake,
Ronald M. Salomon,
Myung A Lee
Publication year - 2020
Publication title -
journal of clinical psychopharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.786
H-Index - 121
eISSN - 1533-712X
pISSN - 0271-0749
DOI - 10.1097/jcp.0000000000001205
Subject(s) - lurasidone , risperidone , olanzapine , positive and negative syndrome scale , clozapine , schizophrenia (object oriented programming) , psychopathology , atypical antipsychotic , antipsychotic , medicine , quetiapine , psychology , psychiatry , psychosis
In addition to clozapine, other atypical antipsychotic drugs pharmacologically similar to clozapine, for example, olanzapine, risperidone, and melperone, are also effective in a similar proportion of treatment-resistant schizophrenia (TRS) patients, ~40%. The major goal of this study was to compare 2 doses of lurasidone, another atypical antipsychotic drug, and time to improvement in psychopathology and cognition during a 6-month trial in TRS patients.